Skip to main content

Articles

Page 9 of 42

  1. Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were devel...

    Authors: Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro and Jorge E. Cortes
    Citation: Journal of Hematology & Oncology 2022 15:90
    Content type: Review Published on:

  2. Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors ...

    Authors: Yun Liu, Yang Li, Yuxi Wang, Congcong Lin, Dan Zhang, Juncheng Chen, Liang Ouyang, Fengbo Wu, Jifa Zhang and Lei Chen
    Citation: Journal of Hematology & Oncology 2022 15:89
    Content type: Review Published on:

  3. Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis. In this study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults with R/R AML patients. Patie...

    Authors: Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang and Mingfeng Zhao
    Citation: Journal of Hematology & Oncology 2022 15:88
    Content type: Correspondence Published on:

  4. The development of combination immunotherapy based on the mediation of regulatory mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep understanding of tumor immunology must inv...

    Authors: Liangliang Xu, Chang Zou, Shanshan Zhang, Timothy Shun Man Chu, Yan Zhang, Weiwei Chen, Caining Zhao, Li Yang, Zhiyuan Xu, Shaowei Dong, Hao Yu, Bo Li, Xinyuan Guan, Yuzhu Hou and Feng-Ming Kong
    Citation: Journal of Hematology & Oncology 2022 15:87
    Content type: Review Published on:

  5. LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/re...

    Authors: Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, Wei-Jun Fu, Jie Xu, Jie Liu, Shi-Wei Jin, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang…
    Citation: Journal of Hematology & Oncology 2022 15:86
    Content type: Research Published on:

  6. Metastasis and chemoresistance are major culprits of cancer mortality, but factors contributing to these processes are incompletely understood.

    Authors: Hsin-Yi Chen, Shu-Jou Chan, Xinxin Liu, An-Chi Wei, Ru-In Jian, Kuan-Wei Huang, Yaw-Dong Lang, Jou-Ho Shih, Chun-Chieh Liao, Chiu-Lin Luan, Yu-Tung Kao, Shang-Yin Chiang, Pei-Wen Hsiao, Yuh-Shan Jou, Yunching Chen and Ruey-Hwa Chen
    Citation: Journal of Hematology & Oncology 2022 15:85
    Content type: Research Published on:

  7. The tumor microenvironment (TME), which is regulated by intrinsic oncogenic mechanisms and epigenetic modifications, has become a research hotspot in recent years. Characteristic features of TME include hypoxi...

    Authors: Fusheng Zhang, Haiyang Liu, Meiqi Duan, Guang Wang, Zhenghou Zhang, Yutian Wang, Yiping Qian, Zhi Yang and Xiaofeng Jiang
    Citation: Journal of Hematology & Oncology 2022 15:84
    Content type: Review Published on:

  8. Cancer is one of the leading causes of death worldwide, and the factors responsible for its progression need to be elucidated. Exosomes are structures with an average size of 100 nm that can transport proteins...

    Authors: Mahshid Deldar Abad Paskeh, Maliheh Entezari, Sepideh Mirzaei, Amirhossein Zabolian, Hossein Saleki, Mohamad Javad Naghdi, Sina Sabet, Mohammad Amin Khoshbakht, Mehrdad Hashemi, Kiavash Hushmandi, Gautam Sethi, Ali Zarrabi, Alan Prem Kumar, Shing Cheng Tan, Marios Papadakis, Athanasios Alexiou…
    Citation: Journal of Hematology & Oncology 2022 15:83
    Content type: Review Published on:

  9. Much higher risk of cancer has been found in diabetes patients. Insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF1R) have been extensively studied in both breast cancer and diabetes therapie...

    Authors: Thi Ngoc Quynh Nguyen, Samil Jung, Hai Anh Nguyen, BeomSuk Lee, Son Hai Vu, Davaajargal Myagmarjav, Hye Hyeon Eum, Hae-Ock Lee, Taeyeon Jo, Yeongseon Choi and Myeong-Sok Lee
    Citation: Journal of Hematology & Oncology 2022 15:82
    Content type: Correspondence Published on:

  10. Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 infection. The efficacy of CO...

    Authors: Xi Wu, Lu Wang, Lu Shen, Lin He and Kefu Tang
    Citation: Journal of Hematology & Oncology 2022 15:81
    Content type: Correspondence Published on:

  11. Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the most difficult cancers to treat in both the primary and recurrent settings. GBM presents a unique therapeutic challenge giv...

    Authors: Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, Hakan Cam, Pierre Giglio and Zihai Li
    Citation: Journal of Hematology & Oncology 2022 15:80
    Content type: Review Published on:

  12. Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistanc...

    Authors: Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh and Tetsuya Mitsudomi
    Citation: Journal of Hematology & Oncology 2022 15:79
    Content type: Research Published on:

  13. Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remain...

    Authors: David Kegyes, Catalin Constantinescu, Louise Vrancken, Leo Rasche, Celine Gregoire, Bogdan Tigu, Diana Gulei, Delia Dima, Alina Tanase, Hermann Einsele, Stefan Ciurea, Ciprian Tomuleasa and Jo Caers
    Citation: Journal of Hematology & Oncology 2022 15:78
    Content type: Review Published on:

  14. Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Stu...

    Authors: Qinghua Wu, Li You, Eugenie Nepovimova, Zbynek Heger, Wenda Wu, Kamil Kuca and Vojtech Adam
    Citation: Journal of Hematology & Oncology 2022 15:77
    Content type: Review Published on:

  15. Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking.

    Authors: Ning Xu, Zhenmei Yao, Guoguo Shang, Dingwei Ye, Haixing Wang, Hailiang Zhang, Yuanyuan Qu, Fujiang Xu, Yunzhi Wang, Zhaoyu Qin, Jiajun Zhu, Fan Zhang, Jinwen Feng, Sha Tian, Yang Liu, Jianyuan Zhao…
    Citation: Journal of Hematology & Oncology 2022 15:76
    Content type: Research Published on:

  16. BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor veneto...

    Authors: Thomas E. Lew and John F. Seymour
    Citation: Journal of Hematology & Oncology 2022 15:75
    Content type: Review Published on:

  17. Natural killer (NK)/T-cell lymphomas are aggressive malignancies with a predilection for Asian and South American populations. Epstein–Barr virus (EBV) infection in lymphoma cells is universal. Predominantly e...

    Authors: Eric Tse, Wei-Li Zhao, Jie Xiong and Yok-Lam Kwong
    Citation: Journal of Hematology & Oncology 2022 15:74
    Content type: Review Published on:

  18. Despite tremendous success of molecular targeted therapy together with immunotherapy, only a small subset of patients can benefit from them. Chemotherapy remains the mainstay treatment for most of tumors inclu...

    Authors: Yao Jiang, Wei Huang, Xiaojiao Sun, Xiaozhou Yang, Youming Wu, Jiaojiao Shi, Ji Zheng, Shujie Fan, Junya Liu, Jun Wang, Zhen Liang, Nan Yang, Zhenming Liu and Yanyong Liu
    Citation: Journal of Hematology & Oncology 2022 15:73
    Content type: Correspondence Published on:

  19. Ferroptosis, a novel non-apoptotic form of cell death, can induce tumor cell death and treatment resistance. Lipid metabolism is closely related to ferroptosis; however, the effect of mammary adipocytes on bre...

    Authors: Yizhao Xie, Biyun Wang, Yannan Zhao, Zhonghua Tao, Ye Wang, Guangliang Chen and Xichun Hu
    Citation: Journal of Hematology & Oncology 2022 15:72
    Content type: Correspondence Published on:

  20. Authors: Jadwiga Węcławek-Tompol, Zuzanna Zakrzewska, Olga Gryniewicz-Kwiatkowska, Filip Pierlejewski, Ewa Bień, Agnieszka Zaucha-Prażmo, Olga Zając-Spychała, Anna Szmydki-Baran, Agnieszka Mizia-Malarz, Wioletta Bal, Małgorzata Sawicka-Żukowska, Agnieszka Kruk, Tomasz Ociepa, Anna Raciborska, Agnieszka Książek, Tomasz Szczepański…
    Citation: Journal of Hematology & Oncology 2022 15:71
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:163

  21. Advanced pancreatic ductal adenocarcinoma (PDAC) is usually an incurable malignancy that needs newer therapeutic targets. Interleukin-1 receptor accessory protein (IL1RAP) is an innate immune mediator that reg...

    Authors: Yang Zhang, Xiaoyi Chen, Huamin Wang, Shanisha Gordon-Mitchell, Srabani Sahu, Tushar D. Bhagat, Gaurav Choudhary, Srinivas Aluri, Kith Pradhan, Plabani Sahu, Milagros Carbajal, Hui Zhang, Beamon Agarwal, Aditi Shastri, Robert Martell, Daniel Starczynowski…
    Citation: Journal of Hematology & Oncology 2022 15:70
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:100

  22. International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term tr...

    Authors: Corinne Frere, Dominique Farge, Deborah Schrag, Pedro H. Prata and Jean M. Connors
    Citation: Journal of Hematology & Oncology 2022 15:69
    Content type: Correspondence Published on:

  23. Although chimeric antigen receptor (CAR)-modified adoptive T cell therapy is a promising immunotherapy for hematological malignancies, the efficacy improvement in relapsed/refractory acute lymphoblastic leukem...

    Authors: Peilong Lai, Xiaomei Chen, Yulian Wang, Jinghua Wang, Yuchen Zhang, Suxia Geng, Peng Li, Xin Du, Jianyu Weng and Duanqing Pei
    Citation: Journal of Hematology & Oncology 2022 15:68
    Content type: Correspondence Published on:

  24. Although messenger RNA (mRNA) vaccines have established efficacy for prevention of severe SARS-CoV2 infection in the general population, their effectiveness in patients with malignancy, especially those on ant...

    Authors: Anthony Rooney, Cory Bivona, Ben Liu, David Streeter, Han Gong and Qamar Khan
    Citation: Journal of Hematology & Oncology 2022 15:67
    Content type: Letter to the Editor Published on:

  25. The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patie...

    Authors: Wei Kang, Jessica J. P. Shami, Vincent K. C. Yan, Xuxiao Ye, Joseph E. Blais, Xue Li, Victor H. F. Lee, Celine S. L. Chui, Francisco T. T. Lai, Eric Y. F. Wan, Carlos K. H. Wong, Ian C. K. Wong and Esther W. Chan
    Citation: Journal of Hematology & Oncology 2022 15:66
    Content type: Brief Report Published on:

  26. Conditioning of the bone marrow prior to haematopoietic stem cell transplant is essential in eradicating the primary cause of disease, facilitating donor cell engraftment and avoiding transplant rejection via ...

    Authors: James M. Griffin, Fiona M. Healy, Lekh N. Dahal, Yngvar Floisand and John F. Woolley
    Citation: Journal of Hematology & Oncology 2022 15:65
    Content type: Review Published on:

  27. Despite the increased usage of post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation (allo-HSCT), our knowledge of immune reconstitution post-allo-HSCT in the setting of...

    Authors: Chenchen Zhao, Matthew Bartock, Bei Jia, Neal Shah, David F. Claxton, Baldeep Wirk, Kevin L. Rakszawski, Myles S. Nickolich, Seema G. Naik, Witold B. Rybka, W Christopher C. Ehmann, Raymond J. Hohl, Jessica Valentin, Michelle Bernas-Peterson, Emily M. Gerber, Michele Zimmerman…
    Citation: Journal of Hematology & Oncology 2022 15:64
    Content type: Correspondence Published on:

  28. N7-methylguanosine (m7G), one of the most prevalent RNA modifications, has recently attracted significant attention. The m7G modification actively participates in biological and pathological functions by affecti....

    Authors: Yuejun Luo, Yuxin Yao, Peng Wu, Xiaohui Zi, Nan Sun and Jie He
    Citation: Journal of Hematology & Oncology 2022 15:63
    Content type: Review Published on:

  29. Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic chang...

    Authors: Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu…
    Citation: Journal of Hematology & Oncology 2022 15:62
    Content type: Correspondence Published on:

  31. Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed.

    Authors: Jan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, Christoph Röllig, Sebastian Stasik, Lisa Wagenführ, Korinna Jöhrens, Friederike Kuithan, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Ralph Naumann, Björn Steffen, Volker Kunzmann…
    Citation: Journal of Hematology & Oncology 2022 15:60
    Content type: Research Published on:

  32. Single-cell sequencing (SCS) is an emerging high-throughput technology that can be used to study the genomics, transcriptomics, and epigenetics at a single cell level. SCS is widely used in the diagnosis and t...

    Authors: Yingying Han, Dan Wang, Lushan Peng, Tao Huang, Xiaoyun He, Junpu Wang and Chunlin Ou
    Citation: Journal of Hematology & Oncology 2022 15:59
    Content type: Review Published on:

  34. Hodgkin lymphoma is a lymphatic malignancy commonly found in cervical lymph nodes. This study evaluated the worldwide incidence, mortality, associated risk factors, and temporal trends of Hodgkin lymphoma by s...

    Authors: Junjie Huang, Wing Sze Pang, Veeleah Lok, Lin Zhang, Don Eliseo Lucero-Prisno III, Wanghong Xu, Zhi-Jie Zheng, Edmar Elcarte, Mellissa Withers and Martin C. S. Wong
    Citation: Journal of Hematology & Oncology 2022 15:57
    Content type: Research Published on:

  35. Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We rep...

    Authors: Hiroshi Handa, June-Won Cheong, Yasushi Onishi, Hiroatsu Iida, Yukio Kobayashi, Hyeoung-Joon Kim, Tzeon-Jye Chiou, Koji Izutsu, Olga Tsukurov, Xiaofei Zhou, Helene Faessel, Ying Yuan, Farhad Sedarati, Douglas V. Faller, Akiko Kimura and Shang-Ju Wu
    Citation: Journal of Hematology & Oncology 2022 15:56
    Content type: Letter to the Editor Published on:

  36. Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that regulates cell proliferation, survival, and migration. However, its role on human multiple myeloma (MM) cells is largely unknown. In this ...

    Authors: Pan Su, Liuling Xiao, Lingqun Ye, Zhuo Wang, Wei Xiong, Qiang Wang, Xingzhe Ma, Miao Xian, Maojie Yang, Youli Zu, Sai Ravi Pingali, Jianfei Qian and Qing Yi
    Citation: Journal of Hematology & Oncology 2022 15:55
    Content type: Correspondence Published on:

  37. The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established.

    Authors: José Luis Piñana, Lucia López-Corral, Rodrigo Martino, Lourdes Vazquez, Ariadna Pérez, Gabriel Martin-Martin, Beatriz Gago, Gabriela Sanz-Linares, Andrés Sanchez-Salinas, Lucia Villalon, Venancio Conesa-Garcia, María T. Olave, Magdalena Corona, Sara Marcos-Corrales, Mar Tormo, José Ángel Hernández-Rivas…
    Citation: Journal of Hematology & Oncology 2022 15:54
    Content type: Research Published on:

  38. Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mechanisms of ...

    Authors: Wenhan Yang, Kaiping Gao, Youhui Qian, Yongyi Huang, Qin Xiang, Cheng Chen, Qianqian Chen, Yiling Wang, Fuyuan Fang, Qihan He, Siqi Chen, Juan Xiong, Yangchao Chen, Ni Xie, Duo Zheng and Rihong Zhai
    Citation: Journal of Hematology & Oncology 2022 15:53
    Content type: Research Published on:

  39. LncRNA-PACERR plays critical role in the polarization of tissue-associated macrophages (TAMs). In this study, we found the function and molecular mechanism of PACERR in TAMs to regulate pancreatic ductal adeno...

    Authors: Yihao Liu, Minmin Shi, Xingfeng He, Yizhi Cao, Pengyi Liu, Fanlu Li, Siyi Zou, Chenlei Wen, Qian Zhan, Zhiwei Xu, Jiancheng Wang, Baofa Sun and Baiyong Shen
    Citation: Journal of Hematology & Oncology 2022 15:52
    Content type: Research Published on:

  40. Acute myeloid leukemia (AML) is a severe hematologic malignancy prevalent in older patients, and the identification of potential therapeutic targets for AML is problematic. Autophagy is a lysosome-dependent ca...

    Authors: Wonhyoung Seo, Prashanta Silwal, Ik-Chan Song and Eun-Kyeong Jo
    Citation: Journal of Hematology & Oncology 2022 15:51
    Content type: Review Published on:

  41. Authors: Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hashemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh and Alan Prem Kumar
    Citation: Journal of Hematology & Oncology 2022 15:50
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2022 15:18

  42. Chromatin has distinct three-dimensional (3D) architectures important in key biological processes, such as cell cycle, replication, differentiation, and transcription regulation. In turn, aberrant 3D structure...

    Authors: Siwei Deng, Yuliang Feng and Siim Pauklin
    Citation: Journal of Hematology & Oncology 2022 15:49
    Content type: Review Published on:

  43. Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the Pr...

    Authors: Amanda Khoo, Lydia Y. Liu, Taylor Y. Sadun, Amirali Salmasi, Aydin Pooli, Ely Felker, Kathleen E. Houlahan, Vladimir Ignatchenko, Steven S. Raman, Anthony E. Sisk Jr., Robert E. Reiter, Paul C. Boutros and Thomas Kislinger
    Citation: Journal of Hematology & Oncology 2022 15:48
    Content type: Letter to the Editor Published on:

  44. The gut microbiota have long been recognized to play a key role in human health and disease. Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut m...

    Authors: Yuting Lu, Xiangliang Yuan, Miao Wang, Zhihao He, Hongzhong Li, Ji Wang and Qin Li
    Citation: Journal of Hematology & Oncology 2022 15:47
    Content type: Review Published on:

  45. Personalized immunotherapy utilizing cancer vaccines tailored to the tumors of individual patients holds promise for tumors with high genetic heterogeneity, potentially enabling eradication of the tumor in its...

    Authors: Bingfeng Zuo, Yang Zhang, Kangjie Zhao, Li Wu, Han Qi, Rong Yang, Xianjun Gao, Mengyuan Geng, Yingjie Wu, Renwei Jing, Qibing Zhou, Yiqi Seow and HaiFang Yin
    Citation: Journal of Hematology & Oncology 2022 15:46
    Content type: Research Published on:

  46. Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding of nucleotide metabo...

    Authors: Huai-liang Wu, Yue Gong, Peng Ji, Yi-fan Xie, Yi-Zhou Jiang and Guang-yu Liu
    Citation: Journal of Hematology & Oncology 2022 15:45
    Content type: Review Published on:

  47. Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell death (RCD), also known as ...

    Authors: Minru Liao, Rui Qin, Wei Huang, Hong-Ping Zhu, Fu Peng, Bo Han and Bo Liu
    Citation: Journal of Hematology & Oncology 2022 15:44
    Content type: Review Published on:

  49. Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies. Fc gamma receptors (FcγRs) pla...

    Authors: Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige…
    Citation: Journal of Hematology & Oncology 2022 15:42
    Content type: Letter to the Editor Published on:

  50. Chromosome translocations involving mixed lineage leukemia 1 (MLL1) cause acute leukemia in most infants and 5–10% children/adults with dismal clinical outcomes. Most frequent MLL1-fusion partners AF4/AFF4, AF...

    Authors: Xin Li, Yuan Yao, Fangrui Wu and Yongcheng Song
    Citation: Journal of Hematology & Oncology 2022 15:41
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.9
    5-year Journal Impact Factor: 27.1
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2024
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 61

    Usage 2024
    Downloads: 3,430,659
    Altmetric mentions: 1,308

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us